Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Genzyme and activist investor Carl Icahn have agreed to settle their proxy contest. Under the agreement, Icahn will withdraw his own name and those of three other nominees for the board and vote his Genzyme shares in favor of the company’s nominees. In return, Genzyme agreed to appoint two Icahn nominees immediately following the firm’s June 16 annual meeting. In May, Genzyme launched a $2 billion stock buyback program and said it would sell three businesses (C&EN, May 17, page 17).
This article has been sent to the following recipient: